18-Jun-2026
PRNewswire (Thu, 18-Jun 9:41 PM ET)
TipRanks (Thu, 18-Jun 11:15 AM ET)
Novocure falls after late-stage trial setback for cancer treatment device
Seeking Alpha News (Thu, 18-Jun 7:51 AM ET)
NovoCure Reports Phase 3 TRIDENT Trial Topline Results
TipRanks (Thu, 18-Jun 7:48 AM ET)
Business Wire (Thu, 18-Jun 7:00 AM ET)
Novocure Revenue Grows 12% on Global Patient Expansion; New Device Approvals Mark Milestone Quarter
Market Chameleon (Thu, 30-Apr 7:06 AM ET)
Novocure Delivers 12% Revenue Growth in Q1 2026 as Patient Demand for Optune Devices Surges
Market Chameleon (Thu, 30-Apr 4:24 AM ET)
Novocure Reports First Quarter 2026 Financial Results
Business Wire (Thu, 30-Apr 7:00 AM ET)
Novocure to Report First Quarter 2026 Financial Results
Business Wire (Wed, 1-Apr 7:00 AM ET)
Market Chameleon (Thu, 26-Mar 5:19 AM ET)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Novocure Limited - trades on the NASDAQ stock market under the symbol NVCR.
As of June 18, 2026, NVCR stock price declined to $14.28 with 4,037,313 million shares trading.
NVCR has a beta of 1.51, meaning it tends to be more sensitive to market movements. NVCR has a correlation of 0.07 to the broad based SPY ETF.
NVCR has a market cap of $1.65 billion. This is considered a Small Cap stock.
Last quarter Novocure Limited - reported $174 million in Revenue and -$.62 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.13.
In the last 3 years, NVCR traded as high as $45.21 and as low as $9.82.
The top ETF exchange traded funds that NVCR belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.
NVCR has underperformed the market in the last year with a price return of -15.0% while the SPY ETF gained +26.9%. However, in the short term, NVCR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +18.4% vs +13.5% return in SPY. But in the last 2 weeks, NVCR shares have been beat by the market, returning -20.6% compared to an SPY return of -1.1%.
NVCR support price is $17.13 and resistance is $18.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCR shares will trade within this expected range on the day.
